Clinical Trial Update: Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing two treatments in intermediate- and high-risk acute promyelocytic leukemia to assess efficacy in achieving first hematologic re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Promyelocytic Leukemia

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Leukemia, Myelocytic, Acute | Phase 3 | Status: COMPLETED